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Abstract  
BACKGROUND: Bacterial infections are considered as the most important cause of exacerbations 
in patients with chronic obstructive pulmonary disease.  
AIM: To compare the efficacy and tolerability of eight antibiotics empirically administered for 
outpatient treatment of exacerbations of COPD.  
METHODS: We performed an observational study including 343 COPD patients with probable 
bacterial exacerbation (Group A and Group B COPD patients) managed in an outpatient setting. 
Eight antibiotic regimens each used 10 days were evaluated: amoxicillin/clavulonic acid, 
doxycycline, cefuroxime, cefixime, clarithromycin, roxithromycin, ciprofloxacin, and moxifloxacin. All 
patients were followed up for 30 days, with an intermediate visits at 5, 7 and 10 days at which the 
duration of symptoms and the side-effects of the drug were evaluated.  
RESULTS: The clinical success rate varied from 69.8% with doxycycline to 80.9% with 
moxifloxacin. The mean time to relief of symptoms varied from 5.6 days with moxifloxacin to 6.3 
days with amoxicillin/clavulonic acid. Significant increase of the post-treatment FEV1 value was 
registered in all treatment groups. Relapse within the first 20 days was registered in the group 
receiving doxycycline, clarithromycin, and ciprofloxacin. The prevalence of the adverse events was 
low varying from 6.7% with cefuroxime to 11.3% with ciprofloxacin.  
CONCLUSION: Our findings suggest high clinical success rate and high safety of all studied 
regimens. 
 
 
 
 
 
 
 
 
Introduction 
Chronic obstructive pulmonary disease 
(COPD) remains frequent and costly disease 
representing one of the principal demands of the 
public health worldwide. Inhaled tobacco smoke and 
other noxious particles, such as occupational 
exposures and smoke from biomass fuels, are the 
most important exogenous factors that influence 
disease development and progression [1].      
The course of COPD can be affected by acute 
events characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-
day variations and leads to a change in medications, 
known as exacerbations [1]. These acute episodes, 
also characterized by increased airway inflammation 
and physiological deterioration, contribute greatly to 
the morbidity, the disease progression, and to the 
overall diminished quality of life in the subjects with 
COPD [2]. Respiratory infections, environmental and 
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occupational exposures, discontinuation of the regular 
treatment, and worsening of the comorbid conditions 
are considered as causes of exacerbations, but in up 
20% of the cases the cause of exacerbation remains 
unknown [2, 3].  
Respiratory infections account for up to 80% 
of exacerbations, of which bacterial infections are 
involved in around 50-70% of exacerbations [4]. 
Although the role of bacterial infection in acute 
exacerbations of COPD has been debated for many 
years, the investigations with newer research 
techniques (bronchoscopic, bacteriologic, and 
serologic studies) bolster the arguments that bacteria 
do cause exacerbations [5, 6]. Respiratory infections 
account for up to 80% of exacerbations, of which 
bacterial infections are involved in around 50-70% of 
exacerbations [4]. The predominant bacteria 
recovered from the lower airways in patients with 
chronic bronchitis (CB) and COPD exacerbations are 
Streptococcus pneumoniae, Haemophilus influenzae, 
and Moraxella catarrhalis.  Atypical bacteria, e. g. 
Mycoplasma pneumoniae and Chlamidia 
pneumoniae, are implicated in up to 10% of 
exacerbations, whereas viral infections, e. g. influenza 
and parainfluenza viruses, rhinovirus and adenovirus, 
cause up to 30% of episodes of infectious 
exacerbations [7, 8]. On the other hand, studies in 
patients with COPD exacerbations have showed that 
the severity of the disease may be an important 
determinant of the type of microorganism. Namely, in 
mild exacerbations Streptococcus pneumoniae is 
predominant and as forced expiratory volume in one 
second (FEV1) declines Haemophilus influenzae, and 
Moraxella catarrhalis become more frequent, whereas 
Pseudomonas aeruginosa and other enteric bacteria 
usual appear in patients with severe airway 
inflammation. The diagnosis of an exacerbation relies 
exclusively on the clinical presentation of the patient 
complaining of an acute change of symptoms 
(baseline dyspnea, cough, and/or sputum production) 
that is beyond normal day-to-day variation [1].   
The criteria of Anthonisen [9] are still the most 
important classification system to identify patients 
likely to be infected with bacterial pathogens based on 
presentation of clinical symptoms [10, 11]. A type I 
exacerbation was defined as a patient presenting with 
increased dyspnea, sputum volume and purulence. A 
type II exacerbation referred to a patient with two of 
these symptoms, while a type III exacerbation 
occurred when a patient had only one symptom with 
evidence of fever or upper airways infection.  
According to the actual version of Global 
Initiative for Chronic Obstructive Pulmonary Disease 
(GOLD) [1], antibiotics should be given to patients 
with type I exacerbation (Evidence B); with type II 
exacerbation, if increased purulence of sputum is one 
of the two symptoms (Evidence C); as well as in 
patients who require mechanical ventilation (invasive 
or noninvasive) (Evidence B). The recommended 
length of antibiotic therapy is usually 5-10 days 
(Evidence D).  
The goals of treatment for COPD 
exacerbations are to minimize the impact of the 
current exacerbation, as well as to prevent the 
development of subsequent exacerbation. Depending 
on the severity of an exacerbation and/or the severity 
of the underlying disease, an exacerbation can be 
managed in an outpatient or inpatient setting. More 
than 80% of exacerbations can be ambulatory treated 
with antibiotics. Potential indications for hospital 
management of the exacerbation include marked 
increase in symptoms intensity (e.g., sudden 
development of resting dyspnea), severe underlying 
COPD, onset of new physical signs (e.g., cyanosis, 
peripheral oedema), failure to respond to initial 
medical management, presence of serious 
comorbidities (e.g., heart failure, newly occurring 
arrhythmias), etc [1, 12].   
 The present study aims to evaluate efficacy 
and safety of eight antibiotic regimens in the 
outpatient treatment of probable bacterial 
exacerbations in the COPD patients.    
 
Material and Methods 
 An observational study including 343 
outpatients classified as Group A and Group B COPD 
patients  with an  exacerbation of probably bacterial 
etiology, 192 males and 151 females, aged 35 to 78 
years. All participants were informed about the study 
and their written consent was obtained.  
The study was carried out in the period 
December 2012 – March 2013 at the Institute for 
Occupational Health of R. Macedonia, Skopje – WHO 
Collaborating Center and GA
2
LEN Collaborating 
Center. The study of the effects of various 
antimicrobial regimens on the clinical course of 
exacerbations of CB and COPD carried out by 
Miravittles et al [13] was used as a model.   
Including criterion was the presence of a 
probable bacterial exacerbation in Group A and Group 
B COPD patients according to the combined COPD 
assessment [1], i.e. in patients with mild or moderate 
COPD according to the GOLD 2010 classification [14], 
which can be managed on outpatient basis. Diagnosis 
of the exacerbation was defined by the patient’s 
symptoms, using the criteria described by Anthonisen 
et al. [9]. Probable bacterial etiology was established 
when the exacerbation was Anthonisen type I or type 
II if increased purulence of sputum was one of the two 
symptoms. All patients underwent clinical 
examination, spirometry, blood gas measurements, 
ECG, and laboratory analysis. Chest X-ray was 
performed in a part of the patients by indications.  
Excluding criterions were bacterial 
exacerbations in Group C and Group D COPD 
patients, patients with exacerbation type III or type II if 
increased purulence of sputum was not one of the two 
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symptoms, patients with asthma, cystic fibrosis, 
malignancy or pneumonia, patients with known 
hypersensitivity to certain antibiotic and/or patients 
who fulfilled criteria for hospitalization.   
After the diagnosis was established, the 
exacerbations were managed with antibiotics. Eight 
antibiotic regimens each used 10 days were 
evaluated: amoxicillin/clavulonic acid 875 mg/125 mg  
twice daily in 42 patients (12.2%), doxycycline 100 mg 
twice daily initially, then once daily in 43 patients 
(12.5%), cefuroxime 250 mg twice daily in 44 patients 
(12.8%), cefixime 400 mg once daily in 43 patients 
(12.5%), clarithromycin 500 mg twice daily in 42 
patients (12.2%), roxithromycin 150 mg twice daily in 
43 patients (12.5%), ciprofloxacin 500 mg twice daily 
in 44 patients (12.8%), and moxifloxacin 400 mg once 
daily in 42 patients (12.2%). Each antibiotic regimen 
was administered to the next patient who met 
including criterion in the mentioned cyclic order if 
there was no contraindication (i.e. known 
hypersensitivity) for its use. The patients were advised 
to continue the regular treatment of stable COPD, as 
well as to use short-acting bronchodilators when 
needed.    
All patients were followed up for 30 days, with 
an intermediate visits at 5, 7 and 10 days at which 
they were asked about the duration of symptoms and 
the side-effects of the drug. The course of 
exacerbation was evaluated as a function of the 
resolution of the symptoms and the treatment was 
considered to be successful if cure or clinical 
improvement was achieved. The cure was defined as 
complete resolution of the cardinal symptoms, 
whereas the clinical improvement was defined as 
return of the symptoms to the baseline severity. In 
addition, spirometric parameters (FVC, FEV1, 
FEV1/FVC, MEF25, MEF50, MEF775, and MEF25-75) at 
the first visit and at the end of the treatment were 
compared. Relapse rates were registered during a 20 
days follow-up period in the patients with remission of 
the symptoms.  
Statistical analysis was performed using the 
Statistical Package for the Social Sciences (SPSS) 
version 11.0 for Windows. Chi-square test was used 
for testing difference in the prevalence. Comparison of 
the mean time to relief of the symptoms and of the 
mean FEV1 values was performed by independent-
samples t-test. A P-value less than 0.05 was 
considered as statistically significant.  
 
Results 
The characteristics of the study subjects is 
shown Table 1. 
The percentage of clinical success (i.e. 
clinical cure or resolution of the symptoms) was 
similar in the eight groups, varying from 69.8% with 
doxycycline to 80.9% with moxifloxacin (Figure 1). 
Table 1: Characteristics of the study subjects. 
 
Variable 
Study subjects 
(n = 343) 
Males  
Mean age (years) 
 
192 (55.9%) 
48.7  10.4 
Mean duration of  COPD (years) 
 
Patients Group A* 
Patients Group B* 
 
Type I exacerbation ** 
Type II exacerbation ** 
 
Increase in dyspnea 
Increase in sputum volume 
 Increase in sputum purulence 
 
Current smokers  
Pack-years smoked 
Ex-smokers  
Passive smokers  
 
10.9  5.7 
 
147 (42.9%) 
196 (57.1%) 
 
157 (45.8%) 
186 (54.2%) 
 
262 (76.4%) 
239 (69.7%) 
297 (86.6%) 
 
79 (23.0%) 
12.9  5.8 
108 (31.5%) 
84 (24.4%) 
 
Numerical data are expressed as a mean value with standard deviation; the frequencies 
as a number and percentage of examinees with certain variable. COPD: chronic 
obstructive pulmonary disease. * Patients are classified following combined COPD 
assessment according to the Global Initiative for Chronic Obstructive Pulmonary Disease 
(GOLD) updated 2011 [1]. ** Type of exacerbation is defined according to the Anthonisen 
et al. [9] classification. 
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Figure 1: Clinical response to the antibiotic treatment in the eight 
groups. A/C: amoxicillin/clavulonic acid; Dox: doxycycline; Cefur: 
cefuroxime; Cefix: cefixime; Clar: clarithromycin; Rox: 
roxithromycin; Cip: ciprofloxacin; Mox: moxifloxacin. 
 
 
The mean time to complete resolution of the 
symptoms or its return to the baseline severity varied 
from 6.2 days with amoxicillin/clavulonic acid to 5.7 
days with moxifloxacin. The difference in the mean 
time to relief of symptoms between the eight groups 
was statistically non-significant (Figure 2).  
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Figure 2: Mean time to relief of the symptoms in the eight groups. 
A/C: amoxicillin/clavulonic acid; Dox: doxycycline; Cefur: 
cefuroxime; Cefix: cefixime; Clar: clarithromycin; Rox: 
roxithromycin; Cip: ciprofloxacin; Mox: moxifloxacin. 
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Similar results were observed on comparison 
of the time to resolution or to return to the baseline 
severity of the certain symptoms in the eight treatment 
groups (Table 2). 
Table 2: Days to resolution or to return to the baseline severity 
of the certain symptoms. 
Antimicrobial regimen 
Increased  
dyspnea 
(days) 
Increased 
expectoration 
(days) 
Purulence of expectoration 
(days) 
Amoxicillin/clavulonic acid 
Doxycycline 
5.3  1.1 
5.0  1.4  
5.1  1.2 
4.8  1.6 
4.4  1.6 
4.5  1.7 
Cefuroxime 
Cefixime 
5.0  0.7 
5.2  1.5 
4.7  1.4 
4.7  2.0 
4.3  1.1 
4.2  1.3 
Clarithromycin 
Roxythromycin 
5.0  1.4 
4.9  1.8 
4.8  1.7 
4.7  1.1 
4.4  1.4 
4.3  1.5 
Ciprofloxacin 
Moxifloxacin 
4.8  1.7 
4.8  1.1 
4.6  1.1 
4.5  1.4 
4.1  1.6 
4.1  1.2 
    
Data are expressed as a mean value with standard deviation. 
  
The values of spirometric parameters at the 
end of the treatment improved in all groups. Statistical 
difference of the pre- and post-treatment FEV1 value 
was observed in all treatment groups (Table 3). 
Table 3: Comparison of the mean FEV1 value at the first visit 
and at the end of the treatment in the five groups. 
  
Antibiotic regimen 
Pre-treatment 
FEV1 (% pred) 
Post-treatment 
FEV1 (% pred) 
P-value 
Amoxicillin/clavulonic acid 
Doxycycline 
62.3  5.8 
60.9  4.7  
67.1  7.4 
68.1  5.8 
.041 
.037 
Cefuroxime 
Cefixime 
61.8  5.9 
59.4  6.3 
67.2  4.7 
66.1  4.9 
.043 
.039 
Clarithromycin 
Roxithromicin 
61.2  5.0 
58.3  7.1 
67.8  5.1 
68.2  4.3 
.046 
.026 
Ciprofloxacin 
Moxifloxacin 
60.2  5.6 
58.9  6.8 
66.6  6.9 
67.1  5.7 
.035 
.029 
    
FEV1: forced expiratory volume in 1 second; % pred: % of predicted value. 
 
Relapse during a 20 days follow-up period in 
the patients with remission of the symptoms was 
registered in the group receiving doxycycline, 
clarithromycin, and ciprofloxacin (2.3%, 2.4%, and 
2.2%, respectively). In the other treatment groups 
there was not any case with relapse of the 
exacerbation in the follow-up period. 
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Figure 3: Prevalence of the side-effects during the treatment in the 
eight groups. A/C: amoxicillin/clavulonic acid; Dox: doxycycline; 
Cefur: cefuroxime; Cefix: cefixime; Clar: clarithromycin; Rox: 
roxithromycin; Cip: ciprofloxacin; Mox: moxifloxacin. 
 
The prevalence of the adverse events during 
the treatment varied from 6.7% with cefuroxime to 
11.3% with ciprofloxacin with no statistical difference 
between the groups (Figure 3).  
In any group there was not serious adverse 
effect that required discontinuation of the treatment. 
Gastrointestinal manifestations (nausea, vomiting, 
epigastric pain, and diarrhoea), followed by headache 
and dizziness were the most frequent adverse events 
(Table 4). 
Table 4: The most frequent adverse effects during the 
treatment in the eight groups. 
 
Antibiotic regimen 
Gastrointestinal 
manifestations 
 (%) 
Headache 
(%) 
Dizziness 
(%) 
Amoxicillin/clavulonic acid 
Doxycycline 
9.5 
9.3 
4.7 
2.3 
/ 
2.3 
Cefuroxime 
Cefixime 
4.5 
4.6 
2.2 
/ 
/ 
2.3 
Clarithromycin 
Roxithromycin 
9.5 
9.3 
/ 
/ 
/ 
2.3 
Ciprofloxacin 
Moxifloxacin 
11.3 
7.1 
2.2 
4.7 
2.2 
/ 
    
Data are expressed as a percentage of patients with certain adverse event. 
 
 
Discussion 
Exacerbations of COPD have serious 
negative impact on patient quality of life, lung function, 
and socioeconomic costs so their prevention, early 
detection, and prompt treatment have a great 
importance in the management of the disease. The 
total of COPD-related expenses for outpatients care in 
the European Union countries is € 4.7 billion per year 
[15]. There is still debate about how exacerbations 
should be defined and graded, and their mechanisms 
are not well understood. The routine treatment of 
exacerbations with antibiotics remains controversial 
but there is no doubt that antibiotics are of benefit with 
exacerbations of a bacterial origin [16].   
In the present study we compared the efficacy 
and tolerability of eight antibiotic regimens empirically 
administered for outpatient treatment of exacerbations 
of Group A and Group B COPD patients. The choice 
of the antimicrobial regimens was done in accordance 
to the actual recommendations [1, 14, 17]. The 
diagnosis of exacerbation was based on the presence 
of clinical symptoms and lung function measurements 
without microbiological evaluation of the sputum. 
According to the actual recommendations, sputum 
analysis should be reserved for patients with frequent 
exacerbations and for chronic purulent sputum in 
whom the presence of more virulent and/or more 
resistant bacteria is likely [3, 18].  
Examined subjects were divided in eight 
groups balanced in all their demographic, clinical, and 
functional characteristics, as well as in the severity of 
the exacerbations. We found a large proportion of 
active and passive smokers among examined 
subjects that was similar to its prevalence in adults 
documented in our previous studies [19, 20].  
The regional pattern of resistance to 
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respiratory pathogens has a great impact on the 
choice of appropriate antibiotic regimen for treatment 
of acute exacerbations of COPD. Prevalence rates of 
beta-lactamase production of up to 40% for penicillin-
resistant Streptococcus pneumoniae have been 
reported in Spain and in the USA, and 58% in the 
Hungary, although in other countries, such as 
Germany and the UK, the prevalence rates are less 
than 5% [5, 21, 22]. Second-generation macrolides 
are considered to be the first-line treatment by 
Canadian Guidelines [23], whereas the Spanish 
authors [24] observed low efficacy of these agents 
due to the high rates of resistance (up to 35%) shown 
by Haemophilus influenzae. On the other hand, actual 
guidelines [14, 25] recommend use of some older 
antibiotics (e.g. trimethoprime/ sulfamethoxasole and 
tetracycline) for which ten years ago by some authors 
[26] has been suggested not to be used in the 
treatment of exacerbations of chronic bronchitis and 
COPD. Results from the present study indicated high 
clinical success rate and time-course of the recovery 
that did not differ significantly between examined 
treatment options. Similar results were obtained in our 
previous study on efficacy and safety of five 
antimicrobial regimens (amoxicillin/clavulonic acid, 
cefuroxime, cefixime, clarithromycin, and 
ciprofloxacin) in the outpatient treatment of  
exacerbations of CB and COPD [27]. Similar effects of 
amoxicillin/clavulonic acid, cefuroxime, clarithromycin, 
and moxifloxacin were reported by the MOSAIC study 
[28], the IMPAC study [29], and the MAESTRAL study 
[30]. Similar results were also reported by Siempos et 
al. [31] in the meta-analysis of effectiveness of 
amoxicillin/clavulonate, macrolides, and quinolones in 
the treatment of acute exacerbations of CB. In the 
present study we found low proportion of the subjects 
with adverse events in all treatment groups similarly to 
the results of studies reviewed [32-34].       
 The present study had some limitations. The 
results should be viewed with caution, since the study 
was neither blinded nor randomised and, it is, 
therefore, subject to possible selection bias in favor of 
one treatment or another. On the other hand, 
relatively small number of the subjects in the different 
treatment groups could have certain implications on 
the data obtained and its interpretation. Relapses 
between days 10 and 30 appeared to be very 
infrequent due to the short time of observation. The 
strength of the study is the number of antibiotic 
regimens studied, as well as the studying of only 
exacerbated subjects with COPD, not exacerbated 
subjects with both CB and COPD. 
In conclusion, in an observational study of 
efficacy and tolerability of eight antibiotic regimens 
(amoxicillin/clavulonic acid, doxycycline, cefuroxime, 
cefixime, clarithromycin, roxithromicin, ciprofloxacin, 
and moxifloxacin) in the outpatient treatment of the 
exacerbations in Group A and Group B COPD 
patients we found high clinical success rate, as well 
as similar time to relieve the symptoms of all regimens 
studied. Low incidence of adverse events indicated 
high tolerability of all treatment options. Our findings 
suggest that each of the examined options should be 
considered as a first choice antibiotic in the outpatient 
treatment of the exacerbations in Group A and Group 
B COPD patients.    
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